Aviragen Therapeutics (NASDAQ: AVIR) is one of 289 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Aviragen Therapeutics to similar businesses based on the strength of its risk, earnings, dividends, analyst recommendations, valuation, profitability and institutional ownership.
Valuation and Earnings
This table compares Aviragen Therapeutics and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Aviragen Therapeutics||$8.90 million||-$29.40 million||-1.06|
|Aviragen Therapeutics Competitors||$290.27 million||$35.99 million||57.36|
This is a breakdown of recent ratings and recommmendations for Aviragen Therapeutics and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aviragen Therapeutics Competitors||1133||3423||11925||240||2.67|
Aviragen Therapeutics presently has a consensus price target of $5.00, suggesting a potential upside of 636.38%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.61%. Given Aviragen Therapeutics’ higher possible upside, equities analysts clearly believe Aviragen Therapeutics is more favorable than its competitors.
Insider and Institutional Ownership
25.0% of Aviragen Therapeutics shares are owned by institutional investors. Comparatively, 49.6% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 4.9% of Aviragen Therapeutics shares are owned by company insiders. Comparatively, 17.4% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares Aviragen Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aviragen Therapeutics Competitors||-5,441.68%||-162.70%||-35.92%|
Volatility and Risk
Aviragen Therapeutics has a beta of -0.09, meaning that its share price is 109% less volatile than the S&P 500. Comparatively, Aviragen Therapeutics’ competitors have a beta of 6.62, meaning that their average share price is 562% more volatile than the S&P 500.
Aviragen Therapeutics competitors beat Aviragen Therapeutics on 10 of the 13 factors compared.
Aviragen Therapeutics Company Profile
Aviragen Therapeutics, Inc., formerly Biota Pharmaceuticals, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.
Receive News & Ratings for Aviragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aviragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.